8 results about "Diabetic heart" patented technology

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

The present invention relates to a composition for preventing or treating diabetic cardiomyopathy comprising an MsrB2 activator as an active ingredient. The MsrB2 activator disclosed in the present invention suppresses oxidative damage of ROS, induces autophagy in mitophagy, increases mitochondrial regeneration and biosynthesis in diabetic heart tissue, thereby suppressing overall myocardial function decline, so that it can be effectively used in a pharmaceutical composition or health food composition for preventing or treating diabetic cardiomyopathy, particularly diabetic heart disease in lean diabetes.

This invention provides a computer-aided analysis system based on high-throughput sequencing data and knowledge graphs, including a data access agent, a quality control analysis agent, a species annotation agent, a knowledge graph reasoning agent, a report generation agent, and an agent scheduling center. The data access agent acquires sequencing data and clinical phenotypic data; the quality control analysis agent performs quality control using the Illumina NovaSeq platform, V3-V4 primers, the SILVA v144 database, Q30 ≥ 90%, and sequences ≥ 50 bp; the species annotation agent performs species classification annotation based on a reference database; the knowledge graph reasoning agent performs association analysis based on a microbiome-disease-intervention knowledge graph, using ET_MGNN and RTGN models, including 264 search keywords covering dental caries, periodontitis, oral cancer, Alzheimer's disease, diabetes, and heart disease; the report generation agent generates personalized analysis reports and intervention suggestions; and the agent scheduling center manages and dynamically schedules all agents, forming a complete closed loop of "perception → analysis → diagnosis → intervention → execution → feedback".

The invention relates to the field of cell biology and biological medicine, and discloses application of FRSR (Ferroptosis Related Small RNA) and FRSR mimics related to ferroptosis and a product of the FRSR mimics related to ferroptosis, which have important application in detection, diagnosis and treatment of ferroptosis and high glucose damage. Wherein the nucleotide sequence of the small non-coding FRSR is as shown in SEQ ID NO. 1. According to the invention, overexpression of FRSR in the heart is realized by constructing a high-glucose injury model, utilizing an in-vitro experimental model and using FRSR mimics, so that it is explained that overexpression of FRSR can alleviate ferroptosis and improve the heart function after high-glucose injury, and a new idea and basis are provided for alleviating diabetic heart disease and researching and developing targeted drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to application of baicalin serving as an SGLT2 inhibitor to treatment of diabetic heart failure. The invention provides the baicalin as a natural SGLT2 inhibitor stimulant for the first time, and the baicalin is used for improving ejection fraction retention heart failure and diabetes related cardiovascular diseases. Molecular docking proves that the binding energy (-9.1 kcal / mol) of the baicalin and the SGLT2 is equivalent to that of phlorizin, and the structural similarity reaches 51.54%. Animal experiments show that 50 mg / kg / day of baicalin can significantly reduce the weight of a classical diabetes model mouse induced by high fat-STZ (Sequence Tagliflozin) by 8.73%, p < t >, 0.01, postprandial blood sugar by 22.7% in 60 min and cardiac hypertrophy indexes by heart weight / weight ratio reduction, p < t >, 0.001, and improve the left ventricular ejection fraction by 21.3%, and has no statistical difference from empagliflozin (EMPA, SGLT-2 inhibitor on the market in China in 2017) in effect. The invention provides a novel natural medicine scheme for HFpEF treatment.

The invention provides an application of berberine hydrochloride and mulberry leaf extract in preparation of a composition for preventing, delaying or treating diabetic cardiomyopathy related symptoms. According to the application, berberine hydrochloride and a mulberry leaf extract are combined for use, and the composition for treating or improving the symptoms related to the diabetic cardiomyopathy is prepared. The combination of berberine hydrochloride and mulberry leaf extract can significantly relieve the symptoms of diabetic cardiomyopathy, including but not limited to promotion of structural growth and functional protein synthesis of myocardial cells of patients with diabetic cardiomyopathy, and optimization of stress response and electrophysiological homeostasis of myocardial cells. The traditional Chinese medicine composition can regulate and control energy metabolism disorder, myocardial apoptosis, cardiac microcirculation disorder and the like of patients, and has great potential in the fields of diabetes mellitus cardiac function protection and whole body health management as a composition component.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating diabetic cardiac autonomic neuropathy and application. The traditional Chinese medicine composition comprises the following components: cassia twigs, honey-fried licorice roots, rhizoma polygonati, almonds, amomum kravanh, coix seeds, astragalus membranaceus, mangnolia officinalis, ginger processed pinellia, fermented soybeans, poria cocos and salvia miltiorrhiza. The traditional Chinese medicine composition follows the compatibility principle of monarch, minister, assistant and guide, the traditional Chinese medicine raw materials are scientifically compounded, the medicines are mutually assisted and compatible, and dialectical treatment is carried out from the perspective of yang deficiency and dampness obstruction, so that the prepared traditional Chinese medicine composition can obviously improve the clinical symptoms such as palpitation, chest distress, weakness and shortness of breath and the heart rate variability index of patients with diabetic cardiac autonomic neuropathy, and the curative effect is good. Moreover, the traditional Chinese medicine has small toxic and side effects after being taken for a long time, and is safe and reliable to take.